 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Five Prime Therapeutics, Inc. (FPRX) is biotechnology company. The firm focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes in the United States.
The companys product candidates include FPA008, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase 1a/1b clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase 1/2 clinical trial for the treatment of pigmented villonodular synovitis tumor, as well as conducts Phase I clinical trial for the treatment of rheumatoid arthritis.
Its product candidates also comprise FPA144, an antibody that inhibits fibroblast growth factor receptor 2b and is in Phase I clinical trials to treat patients with gastric cancer; and FP-1039/GSK3052230, a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors. The companys FP-1039/GSK3052230 is in Phase Ib clinical trials to treat patients with lung cancer and malignant pleural mesothelioma.
It has license and collaboration agreement with GlaxoSmithKline LLC, Bristol-Myers Squibb Company, and UCB Pharma S.A.; and license agreement with Galaxy Biotech, LLC, INBRX 110 LP, The Regents of the University of California, BioWa, Inc., Board of Trustees of the Leland Stanford Junior University, Lonza Sales AG, and National Research Council of Canada.
Yesterday at the 2016 American Association for Cancer Research (AACR) Annual Meeting in New Orleans the company presented two positive research papers titled "FPA144, a Therapeutic Monoclonal Antibody Targeting the FGFR2b Receptor, Promotes Antibody Dependent Cell-Mediated Cytotoxicity and Stimulates Sensitivity to PD-1 the 4T1 Breast Tumor Model in Mice," and “FPA144: A Therapeutic Monoclonal Antibody with Enhanced Antibody Dependent Cell Killing for the Treatment of Fibroblast Growth Factor Receptor 2b Overexpressing Cancers.”
Shares have formed a bullish "cup and handle" and are in the late stage of a breakout. Higher share prices are expected for this stock.
52-Weeks Trading Range: $14.70 - $48.04
Entry Point: $46.40
Stop Loss: $44.05
Target Price: $51.26
FPRX closed at $40.00
